Myocardial T1 Mapping : Hope or Hype?

DOI Web Site Web Site PubMed 被引用文献8件 参考文献78件
  • Bulluck Heerajnarain
    The Heart Hospital Imaging Centre and Barts Heart Centre Institute of Cardiovascular Science, University College London The Hatter Cardiovascular Institute, University College London
  • Maestrini Viviana
    The Heart Hospital Imaging Centre and Barts Heart Centre Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology & Geriatric Sciences, Sapienza University
  • Rosmini Stefania
    The Heart Hospital Imaging Centre and Barts Heart Centre
  • Abdel-Gadir Amna
    The Heart Hospital Imaging Centre and Barts Heart Centre Institute of Cardiovascular Science, University College London
  • Treibel Thomas A
    The Heart Hospital Imaging Centre and Barts Heart Centre Institute of Cardiovascular Science, University College London
  • Castelletti Silvia
    The Heart Hospital Imaging Centre and Barts Heart Centre
  • Bucciarelli-Ducci Chiara
    Cardiology Department, Bristol Heart Institute, Bristol NIHR Cardiovascular BRU, University of Bristol
  • Manisty Charlotte
    The Heart Hospital Imaging Centre and Barts Heart Centre Institute of Cardiovascular Science, University College London
  • Moon James C.
    The Heart Hospital Imaging Centre and Barts Heart Centre Institute of Cardiovascular Science, University College London

書誌事項

タイトル別名
  • Myocardial T1 Mapping
  • – Hope or Hype? –

この論文をさがす

抄録

Cardiovascular magnetic resonance is a well-established tool for the quantification of focal fibrosis. With the introduction of T1 mapping, diffuse myocardial processes can be detected and quantified. In particular, infiltration and storage disorders with large disease-related changes, and diffuse fibrosis where measurement is harder but the potential impact larger. This has added a new dimension to the understanding and assessment of various myocardial diseases. T1 mapping promises to detect early disease, quantify disease severity and provide prognostic insights into certain conditions. It also has the potential to be a robust surrogate marker in drug development trials to monitor therapeutic response and be a prognostic marker in certain diseases. T1 mapping is an evolving field and numerous factors currently preclude its standardization. In this review, we describe the current status of T1 mapping and its potential promises and pitfalls. (Circ J 2015; 79: 487–494)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (3), 487-494, 2015

    一般社団法人 日本循環器学会

被引用文献 (8)*注記

もっと見る

参考文献 (78)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ